MedTrace Logo

Non-invasive MRI Subclassification of Heptocellular Carcinoma - HepCaSt-Study

NCT05202015 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2022-01-21

No results posted yet for this study

Summary

Non-invasive MRI subclassification of Heptocellular Carcinoma - HepCaSt-Study

Conditions

Interventions

DRUG

MRI using a hepatobiliary phase contrast agent (Gd-EOB-DPTA)

MRI of the liver accoring to our institutional daily routine protocol

Sponsors & Collaborators

  • Bayer

    collaborator INDUSTRY

  • Charite University, Berlin, Germany

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-01
Primary Completion
2024-01-01
Completion
2024-07-01
FDA Drug
Yes

Countries

  • Germany

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05202015 on ClinicalTrials.gov